No representation or warranty is made as to the accuracy, completeness or reliability of the information. Sources that have not been independently verified. The views expressed in this presentation contain information derived from publicly available Please contact Prima BioMed and/or refer to the Companys website for further Should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Accordingly, these slides and the information they contain These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR Supplemental information to management discussion August 6, 2013 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
If Yes is marked, indicate below the file numberĪssigned to the registrant in connection with Rule 12g3-2(b): Not applicable. Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ¨ Indicate by check mark whether the registrant files or will file annual reports under cover of Form
0 kommentar(er)
